blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2422812

EP2422812 - Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  06.01.2017
Database last updated on 02.11.2024
Most recent event   Tooltip06.01.2017Application deemed to be withdrawnpublished on 08.02.2017  [2017/06]
Applicant(s)For all designated states
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080 / US
[2012/09]
Inventor(s)01 / Fung, Sek Chung
922 Beacon Square Ct 425
Gaithersburg, MD 20878 / US
 [2012/11]
Representative(s)Evenson, Jane Harriet, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2012/09]Evenson, Jane Harriet, et al
Mathys & Squire LLP 120 Holborn
London EC1N 2SQ / GB
Application number, filing date11183631.820.02.2004
[2012/09]
Priority number, dateUS20030449069P21.02.2003         Original published format: US 449069 P
[2012/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2422812
Date:29.02.2012
Language:EN
[2012/09]
Search report(s)(Supplementary) European search report - dispatched on:EP26.01.2012
ClassificationIPC:A61K39/395, C07K16/18
[2012/09]
CPC:
C07K16/18 (EP,US); A61P17/02 (EP); A61P43/00 (EP);
A61K2039/505 (EP,US); A61K38/00 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2012/09]
TitleGerman:Verfahren zur Vorbeugung und Behandlung von mit der Ischämie-Reperfusionsverletzung assoziierten Gewebeschäden[2012/09]
English:Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury[2012/09]
French:Procédés pour prévenir et traiter des lésions tissulaires associées à une lésion de reperfusion d'ischémie[2012/09]
Examination procedure29.08.2012Amendment by applicant (claims and/or description)
29.08.2012Examination requested  [2012/41]
15.05.2013Despatch of a communication from the examining division (Time limit: M06)
25.11.2013Reply to a communication from the examining division
10.02.2015Despatch of a communication from the examining division (Time limit: M06)
10.08.2015Reply to a communication from the examining division
01.09.2016Application deemed to be withdrawn, date of legal effect  [2017/06]
30.09.2016Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2017/06]
Parent application(s)   TooltipEP04713419.2  / EP1601377
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20040713419) is  30.09.2009
Fees paidRenewal fee
30.09.2011Renewal fee patent year 03
30.09.2011Renewal fee patent year 04
30.09.2011Renewal fee patent year 05
30.09.2011Renewal fee patent year 06
30.09.2011Renewal fee patent year 07
30.09.2011Renewal fee patent year 08
15.02.2012Renewal fee patent year 09
07.02.2013Renewal fee patent year 10
07.02.2014Renewal fee patent year 11
13.02.2015Renewal fee patent year 12
Penalty fee
Additional fee for renewal fee
29.02.201613   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]WO0035483  (BRIGHAM & WOMENS HOSPITAL [US]) [X] 11 * page 3, lines 25,26 * * page 4, line 24 - page 5, line 27 * * page 45, line 22 - page 47, line 28; example 8 * * page 4, lines 1-5 * * page 9, lines 2-5 * * page 10, lines 21,22 * * page 14, lines 8-12 * [I] 12-15;
 [XI]WO0112212  (BRIGHAM & WOMENS HOSPITAL [US]) [X] 11 * page 3, lines 10-12 * * page 4, lines 24-32 * * page 5, line 12 - page 6, line 10 * * page 5, lines 1-5 * * page 7, lines 21-23 * * page 9, lines 10-14 * * page 14, lines 17,18 * * page 31, line 12 - page 32, line 24 * * page 46, line 19 - page 47, line 12; example 6 * * page 55, line 11 - page 56, line 10; example 11 * [I] 12-15;
 [XI]WO0140451  (JENSENIUS JENS CHRISTIAN [DK], et al) [X] 11 * page 3, lines 21-26 * * page 5, lines 7-11 * * page 34, line 6 - page 38, line 3 * * page 58, line 32 - page 59, line 8; example 2 * * page 46, line 27 - line 32 * [I] 12-15;
 [XI]WO0206460  (JENSENIUS JENS CHRISTIAN [DK], et al) [X] 11 * page 3, lines 31-35 * * page 14, lines 1-18 * * page 29, line 12 - page 32, line 17 * * page 43, lines 9-30; example 2 * * page 4, lines 1,2 * * page 41, lines 12-15 * [I] 12-15;
 [E]WO2004062578  (ALEXION PHARMA INC [US]) [E] 11 * page 3, lines 26,27 * * page 4, lines 18-30 * * page 9, lines 5-10 * * page 10, lines 12-19 *;
 [XYI]  - JORDAN JAMES E ET AL, "Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury", CIRCULATION, (20010918), vol. 104, no. 12, ISSN 0009-7322, pages 1413 - 1418, XP002529368 [X] 11 * abstract * * page 1417, column L, paragraph 2 - page 1418, column L, paragraph 1 * * page 1414, column R, paragraph 2 * [Y] 1-10 [I] 12-15

DOI:   http://dx.doi.org/10.1161/hc3601.095578
 [XI]  - ROOS A ET AL, "Therapeutic Inhibition of the Early Phase of Complement Activation", IMMUNOBIOLOGY, URBAN UND FISCHER VERLAG, DE, (20020101), vol. 205, no. 4-5, ISSN 0171-2985, pages 595 - 609, XP004954100 [X] 11 * abstract * * page 603, paragraph 1 - page 604, paragraph 1 * [I] 12-15

DOI:   http://dx.doi.org/10.1078/0171-2985-00157
 [XI]  - COLLARD C D ET AL, "COMPLEMENT ACTIVATION AFTER OXIDATIVE STRESS. ROLE OF THE LECTIN COMPLEMENT PATHWAY", AMERICAN JOURNAL OF PATHOLOGY, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, (20000501), vol. 156, no. 5, ISSN 0002-9440, pages 1549 - 1556, XP000944307 [X] 11 * abstract * * page 1553, column L, paragraph 2 - column R, paragraph 2 * * page 1556, column L, paragraph 1 * * page 1555, column R, paragraph 2 * [I] 12-15
 [XI]  - PETERSEN STEEN VANG ET AL, "Control of the classical and the MBL pathway of complement activation", MOLECULAR IMMUNOLOGY, PERGAMON, GB, (20001001), vol. 37, no. 14, ISSN 0161-5890, pages 803 - 811, XP002343652 [X] 11 * page 805, column R, paragraph 4 * [I] 12-15

DOI:   http://dx.doi.org/10.1016/S0161-5890(01)00004-9
 [X]  - ENDO M ET AL, "GLOMERULA DEPOSITION OF MANNOSE-BINDING LECTIN (MBL) INDICATES A NOVEL MECHANISM OF COMPLEMENT ACTIVATION IN IGA NEPHROPATHY", NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIVERSITY PRESS, GB, (19980101), vol. 13, no. 8, ISSN 0931-0509, pages 1984 - 1990, XP000874166 [X] 9 * page 1985, column L, paragraph 5 *

DOI:   http://dx.doi.org/10.1093/ndt/13.8.1984
 [XI]  - GRATTONE M L ET AL, "Co-operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine-transfected fibroblasts", IMMUNOLOGY, (199909), vol. 98, no. 1, ISSN 0019-2805, pages 152 - 157, XP002529369 [X] 11 * page 153, column L, paragraph 2 * [I] 12-15

DOI:   http://dx.doi.org/10.1046/j.1365-2567.1999.00839.x
 [A]  - LEHMANN ET AL, "In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver", TRANSPLANT INTERNATIONAL, SPRINGER INTERNATIONAL, BERLIN, DE, (20000101), vol. 13, no. 1, doi:10.1007/S001470050399, ISSN 0934-0874, pages S547 - S550, XP002987247 [A] 1-15

DOI:   http://dx.doi.org/10.1007/s001470050399
 [A]  - ZHAO HUI ET AL, "Murine model of gastrointestinal ischemia associated with complement-dependent injury", JOURNAL OF APPLIED PHYSIOLOGY, (200207), vol. 93, no. 1, ISSN 8750-7587, pages 338 - 345, XP002667026 [A] 1-15

DOI:   http://dx.doi.org/10.1152/JAPPLPHYSIOL.00159.2002
 [A]  - DE VRIES BART ET AL, "Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: Inhibition of late apoptosis and inflammation.", TRANSPLANTATION (BALTIMORE), (20030215), vol. 75, no. 3, ISSN 0041-1337, pages 375 - 382, XP002667027 [A] 1-15

DOI:   http://dx.doi.org/10.1097/01.TP.0000044455.05584.2A
 [A]  - FINK M P, "Thoracoabdominal aortic aneurysm repair: A human model of ischemia/reperfusion-induced cytokine-driven multiple organ dysfunction syndrome", CRITICAL CARE MEDICINE, WILLIAMS AND WILKINGS COMPANY, BALTIMORE, MA, US, (20000101), vol. 28, no. 9, ISSN 0090-3493, pages 3356 - 3357, XP009148590 [A] 1-15
 [Y]  - WELBORN M B ET AL, "The relationship between visceral ischemia, proinflammatory cytokines, and organ injury in patients undergoing thoracoabdominal aortic aneurysm repair", CRITICAL CARE MEDICINE, WILLIAMS AND WILKINGS COMPANY, BALTIMORE, MA, US, (20000901), vol. 28, no. 9, doi:10.1097/00003246-200009000-00013, ISSN 0090-3493, pages 3191 - 3197, XP009148677 [Y] 1-10

DOI:   http://dx.doi.org/10.1097/00003246-200009000-00013
by applicantUS4816567
 WO0035483
 US6171586
 WO0112212
 US6267958
 US2002136719
 US6458360
 US6492403
    - J. APPL. PHYSIOL., (1999), vol. 87, no. 6, pages 2357 - 2361
    - AM J PHYSIOL LUNG CELL MOL PHYSIOL, (2001), vol. 281, pages L1494 - L1499
    - "Thoracoabdominal Aortic Aneurysm Repair", HIGH RISK CARDIAC PATIENTS: A MODIFIED GRAFTING TECHNIQUE. ANGIOLOGY, (1998), vol. 7, pages 118 - 122
    - KOHLER, MILSTEIN, NATURE, (1975), vol. 256, page 495
    - GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103
    - KOZBOR, J. IMMUNOL., (1984), vol. 133, page 3001
    - BRODEUR ET AL., Monoclonal Antibody Production Techniques and Applications, MARCEL DEKKER, INC., (1987), pages 51 - 63
    - MUNSON, POLLARD, ANAL. BIOCHEM, (1980), vol. 107, page 220
    - SANGER, F.S ET AL., PROC. NAT. ACAD. SCI., (1977), vol. 74, pages 5463 - 5467
    - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 554
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
    - MARKS ET AL., BIO/TECHNOLOGY, (1992), vol. 10, pages 779 - 783
    - WATERHOUSE ET AL., NUC. ACIDS. RES., (1993), vol. 21, pages 2265 - 2266
    - MORRISON ET AL., PROC. NAT. ACAD. SCI. USA, (1984), vol. 81, page 6851
    - "Continuously Proliferating Human Cell Lines Synthesizing Antibody of Predetermined Specificity", ZURAWAKI, V. R. ET AL., Monoclonal Antibodies, PLENUM PRESS, (1980), pages 19 - 33
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
    - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, no. 1, pages 534 - 1536
    - HOOGENBOOM, WINTER, J. MOL. BIOL., (1991), vol. 227, page 381
    - MARKS, J. MOL. BIOL., (1991), vol. 222, page 581
    - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, (1985), page 77
    - BOE=R ET AL., J. IMMUNOL., (1991), vol. 147, no. 1, pages 86 - 95
    - JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, page 2551
    - JAKOBOVITS ET AL., NATURE, (1993), vol. 362, pages 255 - 258
    - BRUGGERMANN ET AL., YEAR IN IMMUNOL., (1993), vol. 7, page 33
    - DUCHOSAL ET AL., NATURE, (1992), vol. 355, page 258
    - HOOGENBOOM ET AL., J. MOL. BIOL., (1991), vol. 227, page 381
    - VAUGHAN ET AL., NATURE BIOTECH, (1996), vol. 14, page 309
    - SURESH ET AL., METHODS IN ENZYMOLOGY, (1986), vol. 121, page 210
    - COSELLI JS, LEMARIE SA, "Surgical techniques: thoracoabdominal aorta", CARDIOL CLIN NORTH AMER, (1999), vol. 4, pages 751 - 765
    - PETERSEN SV, THIEL S, JENSEN L, STEFFENSEN R, JENSENIUS JC, "An assay for the mannan-binding lectin pathway of complement activation", J IMMUNOL METHODS, (2001), vol. 257, no. 1-2, doi:doi:10.1016/S0022-1759(01)00453-7, pages 147 - 116, XP004311942

DOI:   http://dx.doi.org/10.1016/S0022-1759(01)00453-7
    - FURE H, NIELSEN EW, HACK CE, MOLLNES TE, "A neoepitope-based enzyme immunoassay for quantification of Cl- inhibitor in complex with Clr and CIs", SCAND J IMMUNOL, (1997), vol. 46, no. 6, pages 553 - 557
    - WOLBINK GJ, BOLLEN J, BAARS JW, TENBERGE RJM, SWAAK AJG, PAARDEKOOPER J, HACK CE, "Application of a monoclonal antibody against a neoepitope on activated C4 in an EUSA for the quantification of complement activation via the classical pathway", J IMMUNOL METHODS, (1993), vol. 163, doi:doi:10.1016/0022-1759(93)90240-8, pages 67 - 76, XP023974656

DOI:   http://dx.doi.org/10.1016/0022-1759(93)90240-8
    - MOLLNES TE, BREKKE OL, FUNG M, FURE H, CHRISTIANSEN D, BERGSETH G, VIDEM V, LAPPEGARD KT, KOHL J, LAMBRIS JD, "Essential role of the C5a receptor in E coli-mduced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation", BLOOD, (2002), vol. 100, no. 5, pages 1869 - 1877, XP002440770
    - GARRED P, MOLLNES TE, LEA T, "Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3", SCAND J IMMUNOL, (1988), vol. 27, pages 329 - 335
    - MOLLNES TE, LEA T, FROLAND SS, HARBOE M, "Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex", SCAND J IRNMUNOL, (1985), vol. 22, pages 197 - 202
    - VIDEM V., "Heparin in clinical doses primes granulocytes to subsequent activation as measured by myeloperoxidase release", SCAND J IMNUNOL, (1996), vol. 43, no. 4, pages 385 - 390
    - HEGNHOJ J, SCHAFFALITZKY DE MUCKADELL OB, "An enzyme linked immunosorbent assay for measurements of lactoferrin in duodenal aspirates and other biological fluids", SCAND J CLIN LAB INVEST, (1985), vol. 45, no. 6, pages 489 - 495
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.